New biosimilar guidance from EMA allows non-EU comparator
This article was originally published in Scrip
Executive Summary
The revised version of the European Medicines Agency's general guideline on biosimilar medicines has now been published, complete with a number of changes from the original, including the possibility of using a non-EU comparator drug in order to avoid unnecessary clinical testing, and of extrapolating indications in certain cases without clinical data.